Q-omics provides the consensus-scored TMEM211 profile across patient tissues and cancer cell-line models. TMEM211 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TMEM211 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, TMEM211 RNA expression shows 12,414 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, COAD, and UVM as cancer lineages where TMEM211 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM211 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM211 survival associations across molecular data types. TMEM211 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM211 RNA expression–survival associations across cancer types. High TMEM211 expression shows unfavorable associations in ACC and SKCM, but favorable associations in HNSC, BRCA, OV and LUSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for TMEM211 RNA expression.
This table summarizes TMEM211 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM211. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM211 shows lower tumor expression in STAD, BRCA and HNSC and higher tumor expression in COAD, UCEC and READ. The COAD box plot shows higher TMEM211 RNA expression in tumor versus normal tissue (log2 FC = +2.415, t-test p < 0.001).
This table shows molecular features associated with TMEM211 in patient tissues and cancer cell lines. In patient samples, TMEM211 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM211 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
